[1] L.A. Torre, F. Bray, R.L. Siegel, J. Ferlay, J. Lortet-Tieulent, A. Jemal, Global cancer statistics, 2012, CA: a cancer journal for clinicians, 65 (2015) 87-108.
[2] R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2020, CA: a cancer journal for clinicians, 70 (2020) 7-30.
[3] R. Marcos-Gragera, S. Mallone, L.A. Kiemeney, L. Vilardell, N. Malats, Y. Allory, M. Sant, Urinary tract cancer survival in Europe 1999-2007: Results of the population-based study EUROCARE-5, European journal of cancer (Oxford, England : 1990), 51 (2015) 2217-2230.
[4] 国立がん研究センターがん情報サービス, 「がん統計」(全国がん登録および厚生労働省人口動態統計).
[5] Z. Kirkali, T. Chan, M. Manoharan, F. Algaba, C. Busch, L. Cheng, L. Kiemeney, M. Kriegmair, R. Montironi, W.M. Murphy, I.A. Sesterhenn, M. Tachibana, J. Weider, Bladder cancer: epidemiology, staging and grading, and diagnosis, Urology, 66 (2005) 4-34.
[6] H. von der Maase, L. Sengelov, J.T. Roberts, S. Ricci, L. Dogliotti, T. Oliver, M.J. Moore, A. Zimmermann, M. Arning, Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 (2005) 4602-4608.
[7] M.F. Campbell, P.C. Walsh, A.J. Wein, A.W. Partin, R.R. Dmochowski, L.R. Kavoussi, C. Peters, Campbell-Walsh-Wein urology, 12th ed. / editor-in-chief, Alan W. Partin ; editors, Roger R. Dmochowski, Louis R. Kavoussi, Craig A. Peters ed., Elsevier, Philadelphia, Pa., United States, 2021.
[8] M. Babjuk, A. Böhle, M. Burger, O. Capoun, D. Cohen, E.M. Compérat, V. Hernández, E. Kaasinen, J. Palou, M. Rouprêt, B.W.G. van Rhijn, S.F. Shariat, V. Soukup, R.J. Sylvester, R. Zigeuner, EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016, Eur Urol, 71 (2017) 447-461.
[9] S.M. Hammond, Y.M. Altshuller, T.C. Sung, S.A. Rudge, K. Rose, J. Engebrecht, A.J. Morris, M.A. Frohman, Human ADP-ribosylation factor-activated phosphatidylcholine-specific phospholipase D defines a new and highly conserved gene family, The Journal of biological chemistry, 270 (1995) 29640-29643.
[10] I. Lopez, R.S. Arnold, J.D. Lambeth, Cloning and initial characterization of a human phospholipase D2 (hPLD2). ADP-ribosylation factor regulates hPLD2, The Journal of biological chemistry, 273 (1998) 12846-12852.
[11] R.C. Bruntz, C.W. Lindsley, H.A. Brown, Phospholipase D signaling pathways and phosphatidic acid as therapeutic targets in cancer, Pharmacological reviews, 66 (2014) 1033-1079.
[12] Y. Zheng, V. Rodrik, A. Toschi, M. Shi, L. Hui, Y. Shen, D.A. Foster, Phospholipase D couples survival and migration signals in stress response of human cancer cells, The Journal of biological chemistry, 281 (2006) 15862-15868.
[13] C.N. Antonescu, G. Danuser, S.L. Schmid, Phosphatidic acid plays a regulatory role in clathrin-mediated endocytosis, Molecular biology of the cell, 21 (2010) 2944-2952.
[14] W.C. Colley, T.C. Sung, R. Roll, J. Jenco, S.M. Hammond, Y. Altshuller, D. Bar-Sagi, A.J. Morris, M.A. Frohman, Phospholipase D2, a distinct phospholipase D isoform with novel regulatory properties that provokes cytoskeletal reorganization, Current biology : CB, 7 (1997) 191-201.
[15] M. Corrotte, S. Chasserot-Golaz, P. Huang, G. Du, N.T. Ktistakis, M.A. Frohman, N. Vitale, M.F. Bader, N.J. Grant, Dynamics and function of phospholipase D and phosphatidic acid during phagocytosis, Traffic (Copenhagen, Denmark), 7 (2006) 365-377.
[16] M. Nanjundan, F. Possmayer, Pulmonary phosphatidic acid phosphatase and lipid phosphate phosphohydrolase, American journal of physiology. Lung cellular and molecular physiology, 284 (2003) L1-23.
[17] J.H. Cho, J.S. Han, Phospholipase D and Its Essential Role in Cancer, Molecules and cells, 40 (2017) 805-813.
[18] T.C. Walther, R.V. Farese, Jr., The life of lipid droplets, Biochimica et biophysica acta, 1791 (2009) 459-466.
[19] K.M. Henkels, G.P. Boivin, E.S. Dudley, S.J. Berberich, J. Gomez-Cambronero, Phospholipase D (PLD) drives cell invasion, tumor growth and metastasis in a human breast cancer xenograph model, Oncogene, 32 (2013) 5551-5562.
[20] M. Saito, M. Iwadate, M. Higashimoto, K. Ono, Y. Takebayashi, S. Takenoshita, Expression of phospholipase D2 in human colorectal carcinoma, Oncology reports, 18 (2007) 1329-1334.
[21] Y. Zhao, H. Ehara, Y. Akao, M. Shamoto, Y. Nakagawa, Y. Banno, T. Deguchi, N. Ohishi, K. Yagi, Y. Nozawa, Increased activity and intranuclear expression of phospholipase D2 in human renal cancer, Biochemical and biophysical research communications, 278 (2000) 140-143.
[22] M. Utter, S. Chakraborty, L. Goren, L. Feuser, Y.S. Zhu, D.A. Foster, Elevated phospholipase D activity in androgen-insensitive prostate cancer cells promotes both survival and metastatic phenotypes, Cancer letters, 423 (2018) 28-35.
[23] F. Zhang, Z. Wang, M. Lu, Y. Yonekubo, X. Liang, Y. Zhang, P. Wu, Y. Zhou, S. Grinstein, J.F. Hancock, G. Du, Temporal production of the signaling lipid phosphatidic acid by phospholipase D2 determines the output of extracellular signal-regulated kinase signaling in cancer cells, Molecular and cellular biology, 34 (2014) 84-95.
[24] R.C. Bruntz, H.E. Taylor, C.W. Lindsley, H.A. Brown, Phospholipase D2 mediates survival signaling through direct regulation of Akt in glioblastoma cells, The Journal of biological chemistry, 289 (2014) 600-616.
[25] M.C. O'Reilly, S.A. Scott, K.A. Brown, T.H. Oguin, 3rd, P.G. Thomas, J.S. Daniels, R. Morrison, H.A. Brown, C.W. Lindsley, Development of dual PLD1/2 and PLD2 selective inhibitors from a common 1,3,8-Triazaspiro[4.5]decane Core: discovery of Ml298 and Ml299 that decrease invasive migration in U87-MG glioblastoma cells, Journal of medicinal chemistry, 56 (2013) 2695-2699.
[26] Q. Chen, T. Hongu, T. Sato, Y. Zhang, W. Ali, J.A. Cavallo, A. van der Velden, H. Tian, G. Di Paolo, B. Nieswandt, Y. Kanaho, M.A. Frohman, Key roles for the lipid signaling enzyme phospholipase d1 in the tumor microenvironment during tumor angiogenesis and metastasis, Science signaling, 5 (2012) ra79.
[27] D.W. Kang, M.H. Park, Y.J. Lee, H.S. Kim, T.K. Kwon, W.S. Park, S. Min do, Phorbol ester up-regulates phospholipase D1 but not phospholipase D2 expression through a PKC/Ras/ERK/NFkappaB-dependent pathway and enhances matrix metalloproteinase-9 secretion in colon cancer cells, The Journal of biological chemistry, 283 (2008) 4094-4104.
[28] D.W. Kang, M.H. Park, Y.J. Lee, H.S. Kim, C.W. Lindsley, H. Alex Brown, S. Min do, Autoregulation of phospholipase D activity is coupled to selective induction of phospholipase D1 expression to promote invasion of breast cancer cells, International journal of cancer, 128 (2011) 805-816.
[29] S. Kandori, T. Kojima, T. Matsuoka, T. Yoshino, A. Sugiyama, E. Nakamura, T. Shimazui, Y. Funakoshi, Y. Kanaho, H. Nishiyama, Phospholipase D2 promotes disease progression of renal cell carcinoma through the induction of angiogenin, Cancer science, 109 (2018) 1865-1875.
[30] R.L. Grossman, A.P. Heath, V. Ferretti, H.E. Varmus, D.R. Lowy, W.A. Kibbe, L.M. Staudt, Toward a Shared Vision for Cancer Genomic Data, New England Journal of Medicine, 375 (2016) 1109-1112.
[31] H. Watanabe, T. Hongu, M. Yamazaki, Y. Kanaho, Phospholipase D2 activation by p38 MAP kinase is involved in neurite outgrowth, Biochemical and biophysical research communications, 413 (2011) 288-293.
[32] Y. Sun, Y. Fang, M.S. Yoon, C. Zhang, M. Roccio, F.J. Zwartkruis, M. Armstrong, H.A. Brown, J. Chen, Phospholipase D1 is an effector of Rheb in the mTOR pathway, Proceedings of the National Academy of Sciences of the United States of America, 105 (2008) 8286-8291.
[33] F. Tabatabaian, K. Dougherty, M. Di Fulvio, J. Gomez-Cambronero, Mammalian target of rapamycin (mTOR) and S6 kinase down-regulate phospholipase D2 basal expression and function, The Journal of biological chemistry, 285 (2010) 18991-19001.
[34] N. Hatton, E. Lintz, M. Mahankali, K.M. Henkels, J. Gomez-Cambronero, Phosphatidic Acid Increases Epidermal Growth Factor Receptor Expression by Stabilizing mRNA Decay and by Inhibiting Lysosomal and Proteasomal Degradation of the Internalized Receptor, Molecular and cellular biology, 35 (2015) 3131-3144.
[35] B. Purow, Molecular Pathways: Targeting Diacylglycerol Kinase Alpha in Cancer, Clinical cancer research : an official journal of the American Association for Cancer Research, 21 (2015) 5008-5012.
[36] J. Li, C. Pan, A.C. Boese, J. Kang, A.D. Umano, K.R. Magliocca, W. Yang, Y. Zhang, S. Lonial, L. Jin, S. Kang, DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c- JUN-WEE1 Signaling, Clinical cancer research : an official journal of the American Association for Cancer Research, 26 (2020) 3843-3855.
[37] C.H. Tang, C.F. Chen, W.M. Chen, Y.C. Fong, IL-6 increases MMP-13 expression and motility in human chondrosarcoma cells, The Journal of biological chemistry, 286 (2011) 11056- 11066.
[38] B. Franco, S. Guioli, A. Pragliola, B. Incerti, B. Bardoni, R. Tonlorenzi, R. Carrozzo, E. Maestrini, M. Pieretti, P. Taillon-Miller, C.J. Brown, H.F. Willard, C. Lawrence, M. Graziella Persico, G. Camerino, A. Ballabio, A gene deleted in Kallmann's syndrome shares homology with neural cell adhesion and axonal path-finding molecules, Nature, 353 (1991) 529-536.
[39] N. Soussi-Yanicostas, C. Faivre-Sarrailh, J.P. Hardelin, J. Levilliers, G. Rougon, C. Petit, Anosmin-1 underlying the X chromosome-linked Kallmann syndrome is an adhesion molecule that can modulate neurite growth in a cell-type specific manner, Journal of cell science, 111 ( Pt 19) (1998) 2953-2965.
[40] D. González-Martínez, S.H. Kim, Y. Hu, S. Guimond, J. Schofield, P. Winyard, G.B. Vannelli, J. Turnbull, P.M. Bouloux, Anosmin-1 modulates fibroblast growth factor receptor 1 signaling in human gonadotropin-releasing hormone olfactory neuroblasts through a heparan sulfate- dependent mechanism, The Journal of neuroscience : the official journal of the Society for Neuroscience, 24 (2004) 10384-10392.
[41] V. Murcia-Belmonte, P.F. Esteban, J. Martínez-Hernández, A. Gruart, R. Luján, J.M. Delgado-García, F. de Castro, Anosmin-1 over-expression regulates oligodendrocyte precursor cell proliferation, migration and myelin sheath thickness, Brain structure & function, 221 (2016) 1365-1385.
[42] M. Kanda, D. Shimizu, T. Fujii, S. Sueoka, Y. Tanaka, K. Ezaka, H. Takami, H. Tanaka, R. Hashimoto, N. Iwata, D. Kobayashi, C. Tanaka, S. Yamada, G. Nakayama, H. Sugimoto, M. Koike, M. Fujiwara, Y. Kodera, Function and diagnostic value of Anosmin-1 in gastric cancer progression, International journal of cancer, 138 (2016) 721-730.
[43] L. Qi, W. Zhang, Z. Cheng, N. Tang, Y. Ding, Study on molecular mechanism of ANOS1 promoting development of colorectal cancer, PloS one, 12 (2017) e0182964.
[44] J.W. Franses, N.C. Drosu, W.J. Gibson, V.C. Chitalia, E.R. Edelman, Dysfunctional endothelial cells directly stimulate cancer inflammation and metastasis, International journal of cancer, 133 (2013) 1334-1344.
[45] A.M. Witkowska, M.H. Borawska, Soluble intercellular adhesion molecule-1 (sICAM-1): an overview, European cytokine network, 15 (2004) 91-98.
[46] C.K. Shen, B.R. Huang, W.L. Yeh, C.W. Chen, Y.S. Liu, S.W. Lai, W.P. Tseng, D.Y. Lu, C.F. Tsai, Regulatory effects of IL-1β in the interaction of GBM and tumor-associated monocyte through VCAM-1 and ICAM-1, European journal of pharmacology, 905 (2021) 174216.
[47] V. Sundar Rajan, V.M. Laurent, C. Verdier, A. Duperray, Unraveling the Receptor-Ligand Interactions between Bladder Cancer Cells and the Endothelium Using AFM, Biophysical journal, 112 (2017) 1246-1257.
[48] L. Yan, B. Lin, L. Gao, S. Gao, C. Liu, C. Wang, Y. Wang, S. Zhang, M. Iwamori, Lewis (y) antigen overexpression increases the expression of MMP-2 and MMP-9 and invasion of human ovarian cancer cells, International journal of molecular sciences, 11 (2010) 4441-4452.
[49] J.S. Chen, X.H. Huang, Q. Wang, J.Q. Huang, L.J. Zhang, X.L. Chen, J. Lei, Z.X. Cheng, Sonic hedgehog signaling pathway induces cell migration and invasion through focal adhesion kinase/AKT signaling-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9 in liver cancer, Carcinogenesis, 34 (2013) 10-19.
[50] H. Jin, Y. Yu, Y. Hu, C. Lu, J. Li, J. Gu, L. Zhang, H. Huang, D. Zhang, X.R. Wu, J. Gao, C. Huang, Divergent behaviors and underlying mechanisms of cell migration and invasion in non- metastatic T24 and its metastatic derivative T24T bladder cancer cell lines, Oncotarget, 6 (2015) 522-536.
[51] A.K. Kader, L. Shao, C.P. Dinney, M.B. Schabath, Y. Wang, J. Liu, J. Gu, H.B. Grossman, X. Wu, Matrix metalloproteinase polymorphisms and bladder cancer risk, Cancer research, 66 (2006) 11644-11648.
[52] A.K. Kader, J. Liu, L. Shao, C.P. Dinney, J. Lin, Y. Wang, J. Gu, H.B. Grossman, X. Wu, Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness, Clinical cancer research : an official journal of the American Association for Cancer Research, 13 (2007) 2614-2620.
[53] J.F. Liu, C.W. Lee, M.H. Tsai, C.H. Tang, P.C. Chen, L.W. Lin, C.Y. Lin, C.H. Lu, Y.F. Lin, S.H. Yang, C.C. Chao, Thrombospondin 2 promotes tumor metastasis by inducing matrix metalloproteinase-13 production in lung cancer cells, Biochemical pharmacology, 155 (2018) 537- 546.
[54] J. Xue, Z. Chen, X. Gu, Y. Zhang, W. Zhang, MicroRNA-148a inhibits migration of breast cancer cells by targeting MMP-13, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 37 (2016) 1581-1590.
[55] P.J. Boström, L. Ravanti, N. Reunanen, V. Aaltonen, K.O. Söderström, V.M. Kähäri, M. Laato, Expression of collagenase-3 (matrix metalloproteinase-13) in transitional-cell carcinoma of the urinary bladder, International journal of cancer, 88 (2000) 417-423.
[56] M.H. Park, B.-H. Ahn, Y.-K. Hong, D.S. Min, Overexpression of phospholipase D enhances matrix metalloproteinase-2 expression and glioma cell invasion via protein kinase C and protein kinase A/NF-κB/Sp1-mediated signaling pathways, Carcinogenesis, 30 (2009) 356-365.
[57] D.W. Kang, M.K. Park, H.J. Oh, D.G. Lee, S.H. Park, K.Y. Choi, M.L. Cho, S. Min do, Phospholipase D1 has a pivotal role in interleukin-1β-driven chronic autoimmune arthritis through regulation of NF-κB, hypoxia-inducible factor 1α, and FoxO3a, Molecular and cellular biology, 33 (2013) 2760-2772.
[58] M.H. Park, D.W. Kang, Y. Jung, K.-Y. Choi, D.S. Min, Caffeic acid phenethyl ester downregulates phospholipase D1 via direct binding and inhibition of NFκB transactivation, Biochemical and biophysical research communications, 442 (2013) 1-7.
[59] L.V. Madrid, M.W. Mayo, J.Y. Reuther, A.S. Baldwin, Jr., Akt stimulates the transactivation potential of the RelA/p65 Subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38, The Journal of biological chemistry, 276 (2001) 18934-18940.